Novavax delays EU vaccine supply deal amid production problems - source
Source: Reuters
RACE FOR A CURE
MARCH 25, 2021 11:57 AM UPDATED AN HOUR AGO
Exclusive: Novavax delays EU vaccine supply deal amid production problems - source
By Francesco Guarascio, Carl ODonnell
5 MIN READ
BRUSSELS (Reuters) - Novavax is delaying signing a contract to supply its COVID-19 vaccine to the European Union, an EU official involved in the talks told Reuters, as the U.S. biotech company warned it was struggling to source some raw materials.
Prolonging the talks might further complicate the EUs vaccination plans as the bloc had planned to sign a deal early this year for at least 100 million doses of Novavaxs vaccine, with an option for another 100 million.
The EU official, who asked not to named as the talks are confidential, said the company had postponed signing a deal for weeks, citing legal issues in meetings with the blocs vaccine negotiators.
They are slowing down the process of finishing the contract, the official, who attended the meetings, told Reuters.
Informally, a Novavax executive had said a slow pace in negotiations was warranted because the company was having production problems, the EU official said.
-snip-
Read more:
https://www.reuters.com/article/us-health-coronavirus-eu-novavax-exclusi/exclusive-novavax-delays-eu-vaccine-supply-deal-amid-production-problems-source-idUSKBN2BH2GY